GLP-3 30MG
Unlock the future of metabolic health with GLP-3 30MG Vial, a breakthrough synthetic peptide engineered as a potent triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors. This lyophilized powder, delivered in a precision 3mL glass vial at over 99% purity, drives superior weight loss, glycemic control, and energy balance by suppressing appetite, boosting energy expenditure, and optimizing lipid metabolism. Ideal for advanced research into obesity, type 2 diabetes, NAFLD, and NASH, GLP-3 stands out with its innovative structure—including Aib residues, fatty diacid conjugation, and C-terminal amidation—for enhanced stability and prolonged action. Experience the next evolution in peptide innovation for transformative metabolic outcomes.
$411.25
🚚 Free shipping on all orders (US Only )
🔄 All sales are final
FDA Disclaimer:Â The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. All products are for laboratory developmental research USE ONLY. Products are not for human consumption.
Overview
– **Triple Agonist Power**: Targets GLP-1, GIP, and glucagon receptors for comprehensive metabolic regulation and superior weight reduction.
– **Appetite & Energy Mastery**: Suppresses hunger while enhancing energy expenditure and fat metabolism for profound body composition improvements.
– **Glycemic Precision**: Improves insulin sensitivity and glucose control, ideal for type 2 diabetes and related disorders.
– **Lipid & Liver Benefits**: Modulates lipids to lower cardiovascular risks and supports NAFLD/NASH research applications.
– **Research-Grade Excellence**: >99% purity lyophilized powder in a 3mL vial, with advanced modifications for stability and half-life extension.
Structure
GLP-3 30MG is a synthetic peptide with molecular formula C187H291N45O59 and molecular weight approximately 4.3 kDa. Its sequence incorporates key modifications for optimal receptor binding and pharmacokinetics: HXEGTFYXSDVSSYLEGQAAK-OH with steric diacid-EFIAWLVRGRG elements, including Aib (2-Aminoisobutyric acid) for DPP-4 resistance, Leu(Me) (α-Methyl-L-leucine) for stability, Lys(AEEA-γGlu-C20 diacid) conjugation for albumin binding and extended half-life, and C-terminal Ser-NH2 amidation. These features enable multi-receptor agonism at GLP-1R, GIPR, and GCGR, distinguishing it from single-agonist therapies.
Research
GLP-3 30MG Vial represents a pinnacle in peptide research, activating GLP-1, GIP, and glucagon receptors to orchestrate synergistic pathways for metabolic harmony. By mimicking incretin hormones, it amplifies insulin secretion, curbs glucagon release, and promotes hepatic fat oxidation, leading to marked reductions in body weight, HbA1c levels, and lipid profiles in preclinical models. This multi-agonist approach outperforms traditional GLP-1 therapies by addressing appetite, energy homeostasis, and inflammation simultaneously, positioning GLP-3 as a frontrunner for investigating obesity, T2D, NAFLD, and cardiovascular comorbidities through enhanced cAMP signaling, β-arrestin recruitment, and adaptive energy metabolism.
Referenced Citations
Molecular Solutions Peptides. (n.d.). *GLP-3 RT 30mg*. https://mspeptides.com/product/glp-3-rt-30mg/
Nexxgen Peptides. (n.d.). *GLP-3 R 30mg Lyophilized Powder*. https://nexxgenpeptides.com/product/glp-3-r30mg-lyophilized-powder-research-use-only-copy/
Pro Peptide Solutions. (n.d.). *GLP-3 (R) (30 mg)*. https://propeptidesolutions.com/products/reta-glp-3-24mg
Peptide Minds. (n.d.). *RT-GLP3*. https://peptideminds.com/product/glp-3/
Luvion Bio. (n.d.). *GLP-3 | Triple Agonist*. https://luvionbio.com/product/glp-3/